AstraZeneca’s Newest Push in Oncology RWE

December 13, 2022

The pharma giant AstraZeneca has expanded its presence in the chronic lymphocytic leukemia (CLL) space in recent years. Now, according to its VP and global medical franchise head of Hematology Carlos Doti, the company will help support these oncology therapeutic development efforts with a renewed focus using real-world evidence (RWE).

According to Doti, “In the real world, there are special populations that may not have been included in the trial. For example, older patients or those with comorbidities may not have been recruited. Countries around the world will tend to have different standards of care and different comorbidities. Patients may be using other medications that we need to monitor. We need as wide a view as possible and not be limited to a small study population. We need to expand the patient population to include individuals of a different age, ethnicity, and geography. The clinical trial will get you the approval, but after that there is a continuous journey where researchers seek more information and ensure the proper drug is provided to the proper patient.”

To read more, click here.